AstraZeneca to buy Acerta for blood cancer drug

AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.

The deal gives AstraZeneca access to Acerta’s acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, which is currently in clinical trials. ‘We are boosting a key area in our comprehensive oncology portfolio with a late-stage, potential best-in-class medicine that could transform treatment for patients across a range of blood cancers,’ AstraZeneca's chief executive Pascal Soriot said in a statement.

AstraZeneca will pay $2.5 billion (£1.7 billion) up-front for a 55% share of Acerta, followed by $1.5 billion when acalabrutinib is first approved in the US, or at the end of 2018, whichever is sooner.

Related Content

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

news image

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Clinical collaborations drive cancer immunotherapy

27 August 2014 Business

news image

Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials

Most Commented

WHO clarifies glyphosate risks

23 May 2016 Business

news image

UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels

Large HIV vaccine trial to launch in South Africa

24 May 2016 News and Analysis

news image

US funding agency will enlist 5400 people for HIV vaccine study in South Africa in November